SC 13G/A: NLS Pharmaceutics Ltd.
Ticker: NCEL · Form: SC 13G/A · Filed: Nov 21, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | SC 13G/A |
| Filed Date | Nov 21, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sc-13g-a
AI Summary
SC 13G/A filing by NLS Pharmaceutics Ltd..
Risk Assessment
Risk Level: low
FAQ
What type of filing is this?
This is a SC 13G/A filing submitted by Nls Pharmaceutics LTD. (ticker: NCEL) to the SEC on Nov 21, 2024.
What is the risk level of this SC 13G/A filing?
This filing has been assessed as low risk.
How long is this filing?
Nls Pharmaceutics LTD.'s SC 13G/A filing is 4 pages with approximately 1,250 words. Estimated reading time is 5 minutes.
Where can I view the full SC 13G/A filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 1,250 words · 5 min read · ~4 pages · Grade level 7.9 · Accepted 2024-11-21 16:01:13
Filing Documents
- ea0221253-13ga2hafner_nls.htm (SC 13G/A) — 73KB
- 0001213900-24-100972.txt ( ) — 74KB
(a)
Item 1(a). Name of Issuer: NLS Pharmaceutics Ltd.
(b)
Item 1(b). Address of Issuer’s Principal Executive Offices: The Circle 6 8058 Zurich, Switzerland
(a)
Item 2(a). Name of Person Filing: This Statement is filed on behalf of Ronald Hafner.
(b)
Item 2(b). Address of Principal Offices or, if None, Residence: The address of the Reporting Person is: c/o NLS Pharmaceutics Ltd. The Circle 6 8058 Zurich, Switzerland
(c)
Item 2(c). Citizenship: Ronald Hafner is a citizen of Switzerland.
(d)
Item 2(d). Title of Class of Securities: Common Shares, par value CHF 0.80 per share
(e)
Item 2(e). CUSIP Number: H57830103 Item 3. If the Statement is being filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c), check whether the filing person is a: Not applicable. (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G); (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3); (j) A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J); (k) Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:_________________________ CUSIP No. H57830103 13G Page 4 of 5 Pages Item 4. The ownership information with respect to Ronald Hafner is as follows: (a) Amount beneficially owned: 310,958 (1) common shares (b) Percent of class: 8.1% (1)(2) (c) Number of shares as to which such person has: (i) Sole power to vote or direct the vote: 310,958 (1) common shares (ii) Shared power to vote or direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 310,958 (1) common shares (iv) Shared power to dispose or to direct the disposition of: 0 Item 5.
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 20, 2024 (Date) /s/ Ronald Hafner (Signature) Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (s ee 18 U.S.C. 1001).